Glucocorticoid: Major Factor for Reduced Immunogenicity of 2009 Influenza A (H1N1) Vaccine in Patients with Juvenile Autoimmune Rheumatic Disease by Aikawa, Nádia E. et al.
  Universidade de São Paulo
 
2012
 
Glucocorticoid: Major Factor for Reduced
Immunogenicity of 2009 Influenza A (H1N1)
Vaccine in Patients with Juvenile Autoimmune
Rheumatic Disease
 
 
JOURNAL OF RHEUMATOLOGY, TORONTO, v. 39, n. 1, pp. 167-173, JAN, 2012
http://www.producao.usp.br/handle/BDPI/42294
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Patologia - FM/MPT Artigos e Materiais de Revistas Científicas - FM/MCM
The Journal of Rheumatology Volume 39, no. 1
 http://www.jrheum.org/content/39/1/167
 2012;39;167-173J Rheumatol
 
BONFA and ROSA M.R. PEREIRA
MARIA do CARMO S. TIMENETSKY, VILMA S.T. VIANA, IVAN L.A. FRANÇA, ELOISA
CARLA G.S. SAAD, GUILHERME TRUDES, ALBERTO DUARTE, JOAO L. MIRAGLIA, 
NADIA E. AIKAWA, LUCIA M.A. CAMPOS, CLOVIS A. SILVA, JOZELIO F. CARVALHO,
 
(H1N1) Vaccine in Patients with Juvenile Autoimmune Rheumatic Disease
Glucocorticoid: Major Factor for Reduced Immunogenicity of 2009 Influenza A
 
 
1. Sign up for our monthly e-table of contents 
 
 http://www.jrheum.org/cgi/alerts/etoc
2. Information on Subscriptions
 
 http://jrheum.com/subscribe.html
3. Have us contact your library about access options
 
 Refer_your_library@jrheum.com
4. Information on permissions/orders of reprints
 
 http://jrheum.com/reprints.html
rheumatology and related fields.
Gordon featuring research articles on clinical subjects from scientists working in 
 is a monthly international serial edited by Duncan A.The Journal of Rheumatology
167Aikawa, et al: H1N1 vaccine in juvenile ARD 
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2012. All rights reserved.
Glucocorticoid: Major Factor for Reduced
Immunogenicity of 2009 Influenza A (H1N1) Vaccine in
Patients with Juvenile Autoimmune Rheumatic Disease 
NADIA E. AIKAWA, LUCIA M.A. CAMPOS, CLOVIS A. SILVA, JOZELIO F. CARVALHO, CARLA G.S. SAAD,
GUILHERME TRUDES, ALBERTO DUARTE, JOAO L. MIRAGLIA, MARIA do CARMO S. TIMENETSKY, 
VILMA S.T. VIANA, IVAN L.A. FRANÇA, ELOISA BONFA, and ROSA M.R. PEREIRA
ABSTRACT. Objective. To assess the immunogenicity and safety of non-adjuvanted influenza A H1N1/2009 vac-
cine in patients with juvenile autoimmune rheumatic disease (ARD) and healthy controls, because
data are limited to the adult rheumatologic population.
Methods.A total of 237 patients with juvenile ARD [juvenile systemic lupus erythematosus (JSLE),
juvenile idiopathic arthritis (JIA), juvenile dermatomyositis (JDM), juvenile scleroderma, and vas-
culitis] and 91 healthy controls were vaccinated. Serology for anti-H1N1 was performed by hemag-
glutination inhibition assay. Seroprotection rate, seroconversion rate, and factor-increase in geomet-
ric mean titer (GMT) were calculated. Adverse events were evaluated. 
Results. Age was comparable in patients and controls (14.8 ± 3.0 vs 14.6 ± 3.7 years, respectively;
p = 0.47). Three weeks after immunization, seroprotection rate (81.4% vs 95.6%; p = 0.0007), sero-
conversion rate (74.3 vs 95.6%; p < 0.0001), and the factor-increase in GMT (12.9 vs 20.3; p =
0.012) were significantly lower in patients with juvenile ARD versus controls. Subgroup analysis
revealed reduced seroconversion rates in JSLE (p < 0.0001), JIA (p = 0.008), JDM (p = 0.025), and
vasculitis (p = 0.017). Seroprotection (p < 0.0001) and GMT (p < 0.0001) were decreased only in
JSLE. Glucocorticoid use and lymphopenia were associated with lower seroconversion rates (60.4
vs 82.9%; p = 0.0001; and 55.6 vs 77.2%; p = 0.012). Multivariate logistic regression including dis-
eases, lymphopenia, glucocorticoid, and immunosuppressants demonstrated that only glucocorticoid
use (p = 0.012) remained significant.
Conclusion. This is the largest study to demonstrate a reduced but adequate immune response to
H1N1 vaccine in patients with juvenile ARD. It identified current glucocorticoid use as the major
factor for decreased antibody production. The short-term safety results support its routine recom-
mendation for patients with juvenile ARD. ClinicalTrials.gov; NCT01151644. (First Release Nov 15
2011; J Rheumatol 2012;39:167–73; doi:10.3899/jrheum.110721)
Key Indexing Terms:
VACCINE       SAFETY                                      IMMUNOGENICITY
PANDEMIC INFLUENZA A (H1N1)                   CHILDREN                RHEUMATIC DISEASE
From the Division of Rheumatology, the Pediatric Rheumatology Unit, the
Division of Central Laboratory, Hospital das Clínicas, the Instituto
Adolfo Lutz, and the Division of Infectious Diseases, Faculdade de
Medicina da Universidade de São Paulo; Instituto Butantan, Fundação
Butantan; São Paulo, Brazil. 
Supported by grants from Fundação de Amparo à Pesquisa do Estado de
São Paulo (FAPESP 2010/10749-0 to Dr. Bonfa), Conselho Nacional de
Desenvolvimento Científico e Tecnológico (CNPQ 300248/2008-3 to Dr.
Silva, 300665/2009-1 to Dr. Carvalho, 301411/2009-3 to Dr. Bonfa, and
300559/2009-7 to Dr. Pereira), the Federico Foundation (Dr. Silva, Dr.
Carvalho, Dr. Bonfa, Dr. Pereira), and the Butantan Foundation. 
N.E. Aikawa, MD, Division of Rheumatology, Pediatric Rheumatology
Unit, Faculdade de Medicina da Universidade de São Paulo; L.M.A.
Campos, MD, PhD, Pediatric Rheumatology Unit, Faculdade de
Medicina da Universidade de São Paulo; C.A. Silva, MD, PhD; 
J.F. Carvalho, MD, PhD; C.G.S. Saad, MD, Division of Rheumatology,
Faculdade de Medicina da Universidade de São Paulo; G. Trudes, MD,
Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade
de São Paulo; A. Duarte, MD, PhD, Division of Central Laboratory,
Hospital das Clínicas, Faculdade de Medicina da Universidade de São
Paulo; J.L. Miraglia, MD, PhD, Instituto Butantan, Fundação Butantan;
M.C.S. Timenetsky, PhD, Instituto Adolfo Lutz, Faculdade de Medicina
da Universidade de São Paulo; V.S.T. Viana, PhD, Division of
Rheumatology, Faculdade de Medicina da Universidade de São Paulo;
I.L.A. França, MD, Division of Infectious Diseases, Faculdade de
Medicina da Universidade de São Paulo; E. Bonfa, MD, PhD; 
R.M.R. Pereira, MD, PhD, Division of Rheumatology, Faculdade de
Medicina da Universidade de São Paulo.
Address correspondence to Dr. R.M.R. Pereira, Faculdade de Medicina
da Universidade de São Paulo, Disciplina de Reumatologia, Av. Dr.
Arnaldo 455, Cerqueira César, Sao Paulo, SP, Brazil 01246-903. 
E-mail: rosamariarp@yahoo.com
Accepted for publication August 22, 2011.
Infection remains a leading cause of morbidity and mortal-
ity in patients with juvenile autoimmune rheumatic diseases
(ARD). The combined immunosuppressive effects of the
disease itself and its treatment render the individual more
susceptible to infections. Further, intercurrent infections
may contribute to rheumatic disease flares1,2,3. The recent
pandemic caused by the new influenza A H1N1/2009 virus
led to a higher incidence of hospitalization and death than
the annual rates associated with the seasonal influenza
viruses4, especially in immunosuppressed patients. Of note,
vaccination is the most effective measure to control the
spread of the virus and to reduce associated morbidity and
mortality.
Based on concerns that influenza A H1N1/2009-like
viruses would continue to circulate during the next influen-
za season, the 2010 Recommendations of the Advisory
Committee on Immunization Practices stated that all chil-
dren and adolescents aged between 6 months and 18 years
should receive the trivalent seasonal influenza vaccine con-
taining the A/California/7/2009(H1N1)-like virus5. Accord -
ing to these recommendations, vaccination is particularly
important for patients at increased risk for severe complica-
tion, including those with chronic conditions, such as juve-
nile ARD, particularly in patients under immunosuppressive
therapy5.
However, a point of concern is whether the immune
response to this vaccine is significantly impaired by
 rheumatic disease itself and/or its treatment. To date, no
study had evaluated the efficacy and safety of the influenza
A H1N1/2009 vaccine in patients with juvenile ARD. 
A few studies with small populations evaluated the 
immune response to other vaccines in these patients6,7,8.
Kanakoudi-Tsakalidou, et al showed a satisfactory antibody
response to the seasonal influenza immunization in patients
with juvenile rheumatic diseases under immunosuppressive
therapies6. In contrast, studies on immunosuppressed non-
rheumatic children and adolescents, such as those with can-
cer and after kidney transplant, revealed a limited response
to the influenza A H1N1/2009 vaccine9,10.
The aim of our study was to evaluate the immunogenici-
ty and safety of influenza A H1N1/2009 vaccine in patients
with juvenile ARD compared to healthy controls. 
MATERIALS AND METHODS
Patients and controls. A total of 237 outpatients routinely followed at the
Pediatric Rheumatology Unit and the Rheumatology Division of Clinics
Hospital, São Paulo, with juvenile ARD were included. All patients fulfilled
the international classification criteria as follows: for juvenile systemic
lupus erythematosus (JSLE)11, juvenile idiopathic arthritis (JIA)12, juvenile
scleroderma (JScl)13, juvenile dermatomyositis (JDM)14, Behçet disease15,
Takayasu arteritis16, granulomatosis with polyangiitis (previously denoted
Wegener granulomatosis)16, polyarteritis nodosa16, and Henoch-Schönlein
purpura or Kawasaki disease17. A total of 91 age-matched healthy subjects
were concomitantly included in the control group. All participants were ≥
9 and ≤ 21 years old, and exclusion criteria included previous proven infec-
tion by influenza A H1N1/2009; anaphylactic response to vaccine compo-
nents or to egg; previous vaccination with any live vaccine 4 weeks before
or any inactivated vaccine 2 weeks before the study; 2010 seasonal influen-
za vaccination; acute infection resulting in fever over 38˚C at the time of
vaccination; Guillain-Barré syndrome or demyelinating syndromes; blood
transfusion within 6 months; and hospitalization.
Study design. This was a prospective, open study conducted between March
2010 and April 2010. All patients with juvenile ARD were invited by letter
to participate in the public health influenza A H1N1/2009 vaccine cam-
paign at the immunization center of the same hospital. Healthy volunteers
who came to this center seeking vaccination in response to the national
public health campaign were included in the control group. This protocol
was approved by the local institutional review board, and informed consent
was obtained from all participants. The study was registered with clinical-
trials.gov under NCT01151644.
A single intramuscular dose (0.5 ml) of H1N1 A/California/7/2009-like
virus vaccine (A/California/7/2009/Butantan Institute/Sanofi Pasteur) was
administered to all participants. Patients and controls were evaluated on the
day of vaccination (from March 22 to April 2) and after 3 weeks. Blood
samples were obtained from each participant immediately before and 21
days after vaccination. 
Vaccine. A novel monovalent, non-adjuvanted, inactivated, split-virus vac-
cine was supplied by Butantan Institute/ Sanofi Pasteur (São Paulo, Brazil).
The vaccine contained an inactivated split influenza virus with 15 µg
hemagglutinin antigen equivalent to the A/California/7/2009 (H1N1) virus-
like strain (NYMCx-179A), one of the candidate reassortant vaccine virus-
es recommended by the WHO. Embryonated chicken eggs were employed
using the same standard techniques for the production of seasonal, trivalent,
inactivated influenza vaccine. The vaccine was presented in 5-ml multidose
vials with thimerosal (45 µg per 0.5-ml dose) as a preservative. 
Hemagglutination inhibition assay. Antibody levels against H1N1
A/California/7/2009-like virus were evaluated using the hemagglutination
inhibition assay (HIA) at the Adolfo Lutz Institute.
Sera were tested for antibodies to the H1N1 A/California/7/2009
influenza strain supplied by Butantan Institute. Sera were tested at an ini-
tial dilution of 1:10, and at a final dilution of 1:2560. For the purposes of
calculations, negative titers had an assigned value of 1:5, and titers >
1:2560 a value of 1:2560. Samples were tested in duplicate, and geometric
mean values were used in the analysis.
Virus concentrations were previously determined by hemagglutinin
antigen titration, and the HIA test was performed after removing naturally
occurring nonspecific inhibitors from the sera as described18.
The immunogenicity endpoints after vaccination were the seroprotec-
tion rate (titer ≥ 1:40), seroconversion rate (prevaccination titer < 1:10 and
postvaccination HIA titer ≥ 1:40 or prevaccination titer ≥ 1:10 and post-
vaccination titer ≥ 4-fold increase), geometric mean titers (GMT), and fac-
tor-increase in GMT (ratio of GMT after vaccination to GMT before
 vaccination).
Safety assessment. At the day of vaccination, parents were given a 21-day
personal diary card containing the following list of predefined adverse
events: local reactions (pain, redness, swelling, and itching) and systemic
adverse events (arthralgia, fever, headache, myalgia, sore throat, cough,
diarrhea, rhinorrhea, and nasal congestion). Participants were asked to give
“yes/no” responses for each side effect and to return their diary cards at the
second evaluation day (21 days after vaccination). Adverse events that were
not on the list were also reported.
All local reactions were considered related to the influenza A
H1N1/2009 vaccine, while systemic adverse events were analyzed by the
investigators to determine causality. Severe side effects were defined as
those requiring hospitalization or death.
Statistical analysis. The sizes of the juvenile ARD population and controls
gave the study a power of analysis > 95%.
The immunogenicity and safety analyses were descriptive, and 2-sided
95% CI were calculated assuming binomial distributions for dichotomous
variables and log-normal distribution for hemagglutination inhibition titers.
For prednisone and immunosuppressant drug use, seroprotection rate, sero-
conversion rate, and adverse events, Fisher’s exact test was used. GMT
were compared between each subgroup of patients with juvenile ARD and
the control group using a 2-sided Student t test or Mann-Whitney U test on
the log10-transformed titers. The factor-increase in GMT was also calculat-
ed for all participants. Spearman’s correlation was used to compare the
log10-transformed titers and log10-transformed factor-increase with gluco-
168 The Journal of Rheumatology 2012; 39:1; doi:10.3899/jrheum.110721
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2012. All rights reserved.
corticoid dose. Multi variate logistic regression analysis was performed
using seroconversion rate as the dependent variable and the variables with
p < 0.2 in the univariate analyses as independent variables (JSLE, JIA,
JDM, primary vasculitis, glucocorticoid use, concomitant glucocorticoid
and immunosuppressant use, and lymphopenia). All tests were 2-sided, and
significance was set at a p value < 0.05.
RESULTS
In total, 237 patients with the following juvenile ARD were
studied: 99 JSLE, 93 JIA, 18 JDM, 11 JScl [5 systemic scle-
rosis (SSc) and 6 localized scleroderma], and 16 primary
vasculitis (5 Henoch-Schönlein purpura, 3 Takayasu arteri-
tis, 3 granulomatosis with polyangiitis, 3 polyarteritis
nodosa, 1 Kawasaki disease, and 1 Behçet disease), and 91
healthy controls (Table 1). 
Patients and controls were comparable regarding mean
current age (14.8 ± 3.0 yrs vs 14.6 ± 3.7 years, respectively;
p = 0.47), with a predominance of females among patients
with ARD (66% vs 52%; p = 0.02). Mean disease duration
was 5.8 ± 3.7 years. Ninety patients (38%) were taking glu-
cocorticoids, with a mean dose of prednisone 17.4 ± 14.2
mg/day (0.36 ± 0.32 mg/kg/day), and mean glucocorticoid
duration of 43.1 ± 34.5 months, and 84.5% of patients had a
diagnosis of JSLE. Sixty percent (60.3%) of patients were
treated with immunosuppressive agents, and more than half
(51.7%) were under methotrexate (MTX) therapy (Table 1).
Influenza A H1N1/2009 vaccine immunogenicity. Sero -
protec tion and seroconversion rates of patients and controls
are shown in Table 2. At baseline, seroprotective antibody
titer ≥ 1:40 was seen in 22.4% (n = 53) of patients with juve-
nile ARD and 20.9% (n = 19) of controls (p = 0.882; Table
2). After 21 days, the vaccine seroprotection rate was 81.4%
(95% CI 76.5%–86.4%) in patients with juvenile ARD, sig-
nificantly lower than in controls (95.6%; 95% CI
91.4%–99.8%; p = 0.0007). Moreover, following vaccina-
tion, the seroconversion rate was significantly lower in
patients with juvenile ARD compared to controls [74.3%
(95% CI 68.7%–79.9%) vs 95.6% (95% CI 91.4%–99.8%);
p < 0.0001]. As for immunogenicity in each rheumatic dis-
ease, seroprotection rates prior to vaccination were compa-
rable between patients and controls. The postvaccination
seroprotective rate was lower in patients with JSLE com-
pared to controls (p < 0.0001), and a tendency of a reduced
rate was observed in those with primary vasculitis (p =
0.067). Of note, seroconversion rates were reduced in
patients with JSLE (p < 0.0001), JIA (p = 0.008), JDM (p =
0.025), and primary vasculitis (p = 0.017) compared to con-
trols (Table 2).
The GMT values in patients with juvenile ARD and con-
trols are illustrated in Table 3. GMT after immunization
[147.2 (95% CI 119.7–181.1) vs 250.8 (95% CI
196.3–320.3); p = 0.011] and the factor-increase in GMT
[12.9 (95% CI 10.7–15.7) vs 20.3 (95% CI 15.6–26.4); p =
0.012] were significantly lower in the ARD group compared
to the control group. Disease evaluations for specific patient
subgroups revealed lower GMT after immunization and also
a lower factor-increase in GMT only in patients with JSLE
compared to controls (p < 0.0001; Table 3).
Further analysis of the influence of therapy on immuno-
genicity revealed a lower percentage of seroconversion
among patients using glucocorticoids compared to those
without this medication (60.4% vs 82.9%; p = 0.0001).
There was no difference in rates for seroprotection (p =
0.247) or seroconversion (p = 0.279) between patients tak-
ing prednisone < 20 mg/day and those taking ≥ 20 mg/day.
However, a trend for lower GMT and factor-increase in
GMT after vaccination was observed among patients taking
prednisone > 20 mg/day [49.4 (95% CI 28.9–84.7) vs 95.2
(95% CI 63.4–143.1), p = 0.076, and 5.3 (95% CI 3.4–8.3)
vs 9.3 (95% CI 6.6–13.2), p = 0.054, respectively]. Also, a
significant negative correlation was observed regarding glu-
cocorticoid dose and log10-transformed titers (r = –0.36, p <
0.0001), as well as glucocorticoid dose and log10-trans-
formed factor-increase of GMT (r = –0.30, p < 0.0001).
Concerning immunosuppressant use, no differences in
the seroconversion rate (76.4% vs 75.5%; p = 0.763), sero-
protection rate (80.4% vs 83%; p = 0.733), or GMT [130.3
(95% CI 99.3-170.8) vs 177.4 (95% CI 129.7-242.6); p =
0.151] were observed comparing patients taking and not tak-
ing these drugs. The specific analysis of MTX, azathioprine,
cyclosporine, mycophenolate mofetil, leflunomide, and
cyclophosphamide revealed no effects on seroconversion
and seroprotection (p > 0.05) in patients taking and not tak-
ing these drugs. A reduced postvaccination GMT was
observed only for patients taking azathioprine (p = 0.019)
and mycophenolate mofetil (p = 0.01). Concomitant use of
immunosuppressive therapy and glucocorticoid resulted in a
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Table 1. Distributions of rheumatic diseases and therapies in 237 patients.
Data are the mean ± SD or n (%).
Feature
Disease
Juvenile systemic lupus erythematosus 99 (41.8)
Juvenile idiopathic arthritis 93 (39.2)
Juvenile dermatomyositis 18 (7.6)
Juvenile scleroderma 11 (4.6)
Primary vasculitis 16 (6.8)
Treatment
Prednisone 90 (38)
Dose, mg/day 17.4 ± 14.2
Dose, mg/kg/day 0.36 ± 0.32
Dose ≥ 20 mg/day 36 (40)
Duration of glucocorticoid therapy, mo 43.1 ± 34.5
Immunosuppressant 143 (60.3)
Methotrexate 74 (51.7)
Azathioprine 43 (30.1)
Cyclosporine 23 (16.1)
Mycophenolate mofetil 13 (9.1)
Leflunomide 6 (4.2)
Cyclophosphamide 3 (2.1)
lower seroconversion rate compared to patients without
immunosuppressive or glucocorticoid therapy (64.8% vs
78.3%; p = 0.0352).
In the analysis of lymphocyte count, patients with juve-
nile ARD with lymphopenia (lymphocyte count <
1000/mm3) showed a significantly lower seroconversion
rate compared to those without this complication (55.6% vs
77.2%, respectively; p = 0.012).
Multivariate logistic regression was performed to deter-
mine possible deleterious factors for the seroconversion rate
[i.e., disease (JSLE, JIA, JDM, primary vasculitis), lym-
phopenia (lymphocyte count < 1000/mm3), or glucocorti-
coid use or concomitant glucocorticoid and immunosup-
pressant]. Only glucocorticoid use remained significant (OR
0.20, 95% CI 0.06–0.70, p = 0.012; Table 4). Reinforcing
this finding, a significant negative correlation was observed
between glucocorticoid dose and log10-transformed titers 
(r = –0.36, p < 0.0001), as well as between glucocorticoid
dose and log10-transformed factor-increase of GMT (r =
–0.30, p < 0.0001).
Vaccine safety. Local and systemic adverse events reported
within 21 days of vaccination are summarized in Table 5.
Local itching was reported exclusively by patients with
juvenile ARD (p = 0.003). The only systemic reaction more
frequently observed in patients was arthralgia (13.1% vs
2.2% in controls; p = 0.002), with a median duration of 1
(range 1–9) days and median time of appearance after vac-
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Table 2. Seroprotection and seroconversion rates of influenza A (H1N1) 2009 vaccine in patients with rheumatic
disease and controls.
Seroprotection Rate
(titer ≥ 1/40) Seroconversion
N Before Immunization, % After Immunization, % Rate, % (95% CI)
(95% CI) (95% CI)
Control 91 20.9 (12.6–29.3) 95.6 (91.4–99.8) 95.6 (91.4–99.8)
JARD 237 22.4 (17.1–27.7) 81.4 (76.5–86.4)* 74.3 (68.7–79.9)*
JSLE 99 20.2 (12.3–28.1) 73.7 (65.0–82.4)* 63.6 (54.1–73.1)*   
JIA 93 20.4 (12.2–28.6) 88.2 (81.6–94.8) 82.8 (75.1–90.5)*
JDM 18 38.9 (16.4–61.4) 83.3 (66.1–100.5) 77.8 (58.6–97.0)*
JScl 11 27.3 (1.0–53.6) 90.9 (73.9–107.9) 90.9 (73.9–107.9)
Primary vasculitis 16 25.0 (13.8–46.2) 81.3 (62.2–100.4) 75 (53.8–96.2)*
* p < 0.05. JARD: juvenile autoimmune rheumatic diseases; JSLE: juvenile systemic lupus erythematosus; 
JIA: juvenile idiopathic arthritis; JDM: juvenile dermatomyositis; JScl: juvenile scleroderma.
Table 3. Geometric mean titers and factor-increases in the geometric mean titer after influenza A (H1N1) 2009
vaccination in patients with juvenile autoimmune rheumatic disease and controls.
Geometric Mean Titer Factor-increase in
N Before Immunization, % After Immunization, % Geometric Mean Titer
(95% CI) (95% CI) (95% CI)
Control 91 12.4 (9.7–15.7) 250.8 (196.3–320.3) 20.3 (15.6–26.4)
JARD 237 11.4 (9.7–13.3) 147.2 (119.7–181.1)* 12.9 (10.7–15.7)*
JSLE 99 10.9 (8.5–13.9) 91.1 (66.0–125.8)* 8.4 (6.3–11.2)*
JIA 93 10.8 (8.4–13.8) 217.2 (159–296.7) 20.2 (14.8–27.5)
JDM 18 15.3 (8.9–26.3) 201.6 (95.4–425.8) 13.2 (7.2–24.1)
JScl 11 12.1 (6.0–24.2) 181.5 (70.2–469.4) 15.0 (6.3–35.9)
Primary vasculitis 16 14.1 (6.8–29.2) 182.2 (68.1–487.4) 12.9 (5.9–28.2)
* p < 0.05. JARD: juvenile autoimmune rheumatic diseases; JSLE: juvenile systemic lupus erythematosus; 
JIA: juvenile idiopathic arthritis; JDM: juvenile dermatomyositis; JScl: juvenile scleroderma.
Table 4. Multivariate logistic regression analyses including current treat-
ment and lymphopenia as independent variables for seroconversion in
patients with juvenile autoimmune rheumatic diseases after influenza A
(H1N1) 2009 vaccination.
Variable OR (95% CI) p
JSLE 0.36 (0.039–3.33) 0.368
JIA 0.45 (0.05–3.83) 0.47
JDM 0.51 (0.05–5.70) 0.586
Primary vasculitis 0.60 (0.05–7.21) 0.691
Glucocorticoid use 0.20 (0.06–0.70) 0.012
Concomitant use of glucocorticoid plus 2.71 (0.90–8.20) 0.077
immunosuppressant
Lymphopenia 0.61 (0.27–1.38) 0.235
JSLE: juvenile systemic lupus erythematosus; JIA: juvenile idiopathic
arthritis; JDM: juvenile dermatomyositis.
cination of 0 (range 0–12) days. No severe side effects were
observed in patients or controls (Table 5).
DISCUSSION 
Our study is the largest analysis in patients with juvenile
ARD to demonstrate that the non-adjuvanted influenza A
H1N1/2009 vaccine is safe and exhibits a reduced immuno-
genicity associated with glucocorticoid therapy.
This was the first report that evaluated the influenza A
H1N1/2009 vaccine response in a cohort of pediatric
patients with rheumatic diseases. All patients who agreed to
participate were included regardless of disease activity sta-
tus or current treatment, to closely represent the real-life sit-
uation. Also, all patients fulfilled the international criteria
for juvenile ARD, and the study benefited from the inclusion
of a large patient population, an essential requirement to
accurately define vaccine immunoresponse and safety,
which was not met by previous studies of seasonal influen-
za vaccine6,8. Moreover, age-matching of the control group
is essential because effectiveness of vaccine has a distinct
pattern in children and adolescents19. Our report included
only patients over age 9 years, excluding younger children,
who have a lesser humoral response to influenza A
H1N1/2009 vaccine19,20.
This study design provided strong evidence that the
immunoresponse to influenza A H1N1/2009 vaccine was
impaired in the juvenile ARD population, in contrast to pre-
vious studies on seasonal influenza vaccination6,7,8. In this
regard, Malleson, et al evaluated 34 children with chronic
arthritis (91% JIA) and observed similar seasonal vaccine
immunogenicity in patients and 13 controls, independent of
the use of prednisone or immunosuppressive agents7. The
lack of age-matching to controls hampers the interpretation
of their findings due to the inclusion of extremes of age7. In
addition, the adequate humoral response reported for chil-
dren with JIA, JSLE, JDM, and other rheumatic diseases
was also not conclusive due to overrepresentation of JIA in
the sample and the lack of a healthy control group6. On the
other hand, in the study of Ogimi, et al, the 49 patients with
rheumatic disease and 36 with juvenile chronic diseases in
the control group had unexpectedly low immunoresponses
to the seasonal influenza, although it was comparable
between groups8. Again, the inclusion of infants and the
vaccination protocol used in that study may account for the
impaired response that was observed8.
Of note, our disease subgroup analysis revealed a
reduced protective immunogenicity against the pandemic
influenza A H1N1/2009 vaccine in all rheumatic autoim-
mune conditions except JScl. Similarly, we have recently
observed an adequate response for this vaccine in adult
patients with SSc21, and effective humoral and cellular
responses to an adjuvanted virosomal nonpandemic flu vac-
cine were also reported in others with this disease22.
The immunoresponse was considerably compromised in
our patients with JSLE, as indicated by the inadequate post-
seroprotection and postseroconversion rates, deficient
increase in GMT, and low factor-increase in GMT, suggest-
ing a more severely impaired immune state in persons with
this illness that may ultimately affect the response to anti-
genic challenge23. The well-known lupus intrinsic antibody
and cellular dysfunction24 may account for this finding,
which is reinforced by the observation of decreased anti-
body response25 and cell-mediated response to influenza
vaccination in adult SLE26.
With regard to JIA, a diminished vaccine response, deter-
mined by the significantly lower seroconversion rate, was
observed, although it was higher than that in juvenile lupus,
in spite of comparable postimmunization seroprotection,
GMT, and factor-increase in GMT. The preimmunization
rate cannot account for this finding because it was similar to
that of the control group. In contrast, previous reports sug-
gest apparently adequate vaccine responses for seasonal
influenza8 and hepatitis27 in persons with JIA. The inclusion
of patients or controls younger than age 9 years8,27 and 3
years old8 precludes a definitive conclusion about their find-
ings, as vaccine responses in these 2 age brackets are expect-
ed to be much lower than in older children.
Patients with JDM had a deficient seroconversion rate,
which is in accord with a report for the same vaccine in adult
DM21. This finding may be associated with the underlying
pathology of this disease, which is known to involve the
humoral endotheliopathy initiated by complement deposi-
tion in intramuscular blood vessels28.
The lower immune response to vaccine that we observed
in the primary vasculitis group contrasts with the adequate
response in reports concerning adult patients with granulo-
matosis with polyangiitis immunized with seasonal29 and
pandemic H1N1 vaccine21. The most likely explanation for
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Table 5. Adverse events following influenza A (H1N1) 2009 vaccination
in patients with juvenile autoimmune rheumatic diseases (JARD) and con-
trols. Data are n (%).
Adverse Events JARD, Control, p
n = 237 n = 91
Local reactions 60 (25.3) 21 (23.1) 0.78
Pain 43 (18.1) 21 (23.1) 0.35
Redness 9 (3.8) 2 (2.2) 0.73
Swelling 3 (1.3) 2 (2.2) 0.62
Itching 19 (8) 0 (0.0) 0.003
Systemic reactions 84 (35.4) 27 (29.7) 0.36
Arthralgia 31 (13.1) 2 (2.2) 0.002
Fever 13 (5.5) 3 (3.3) 0.57
Headache 41 (17.3) 18 (19.8) 0.63
Myalgia 27 (11.4) 6 (6.6) 0.22
Sore throat 9 (3.8) 5 (5.5) 0.54
Cough 16 (6.8) 5 (5.5) 0.8
Diarrhea 8 (3.4) 2 (2.2) 0.73
Rhinorrhea 19 (8) 3 (3.3) 0.15
Nasal congestion 13 (5.5) 3 (3.3) 0.57
this discrepancy is the limited number of children with pri-
mary vasculitis analyzed in our study and the underrepre-
sentation of granulomatosis with polyangiitis in our sample.
Alternatively, a vaccine response may be affected by
immunosuppressive therapy, and we determined by multi-
variate analysis that glucocorticoid therapy was the main
contributing factor to a reduced immunoresponse in patients
with juvenile ARD. There are conflicting data regarding this
drug30, with a few reports describing no effects on influen-
za vaccine response in children with rheumatic diseases6,7,8.
However, the prednisolone dose was described in only 1 of
these studies, and it was quite low (0.21 ± 0.16 mg/kg),
making it difficult to determine the influence of this drug on
vaccine immunogenicity8. In contrast, others have reported
an attenuated immune response to seasonal influenza vacci-
nation in patients with SLE and asthma under glucocorticoid
therapy25,31. Indeed, Holvast, et al found that glucocorticoid
and/or immunosuppressant was associated with lower
humoral and cell-mediated responses against the H1N1
strain of seasonal influenza vaccine in adult SLE25,26.
Interestingly, in our study the seroconversion rate was not
affected by the use of immunosuppressive drugs other than
glucocorticoid. However, this analysis was uncertain
because MTX represented more than half of the immuno-
suppressive drugs used, and there was a clear bias of indica-
tion by disease. In this regard, an extensive separate analy-
sis of disease activity and drug influence in JSLE and JIA is
under way. Nevertheless, previous studies with pediatric and
adult rheumatic patients have suggested no deleterious
effect of immunosuppressive drugs on antibody responses to
seasonal influenza vaccine6,32,33.
We observed that lymphopenia also reduced serocon-
version to unadjuvanted influenza A H1N1/2009 vaccine
in patients with juvenile ARD. The response to influenza
vaccine depends on adequate antigen processing and pres-
entation, and normal interaction between T and B cells and
their activation25,26. Studies in patients infected with
HIV-1 have shown that anti-influenza-specific antibody
responses correlated with the CD4 T cell count34. Indeed,
HIV-1 infected patients generated poorer responses to
monovalent influenza A H1N1/2009 vaccine compared to
healthy subjects35,36.
For pandemic influenza vaccines to be licensed they must
meet all 3 current immunologic standards established for
seasonal vaccines, which include a percentage of seropro-
tection > 70%, a percentage of seroconversion > 40%, and a
factor-increase in GMT > 2.537,38. These criteria were estab-
lished for healthy adults aged 18 to 60 years, but were also
proposed to be used among the pediatric population39.
Therefore, although our population of patients with juvenile
ARD presented lower percentages of seroprotection and
seroconversion and a lower factor-increase in GMT com-
pared to healthy controls, these patients still achieved all of
the 3 established immunologic thresholds, showing that the
vaccine, while being less immunogenic, was effective in
protecting them.
Influenza A (H1N1) vaccine was well tolerated and safe
in patients with juvenile ARD, as no serious short-term
adverse event was observed. Arthralgia was a more frequent
complaint of patients with juvenile ARD compared to
healthy controls. Studies on influenza A/H1N1 2009 vaccine
in healthy children and adolescents have not reported mus-
culoskeletal complaints19,20, suggesting that the occurrence
of this manifestation could be related to the patient’s genet-
ic background for rheumatic disease40.
Our study revealed a reduced but adequate immune
response to the unadjuvanted influenza A H1N1/2009 vac-
cine in patients with juvenile autoimmune rheumatic dis-
eases, and identified current glucocorticoid use as the major
factor for decreased antibody production. The short-term
safety results support routine recommendation for vaccina-
tion for patients with juvenile ARD.
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